C5 and paroxysmal nocturnal hemoglobinuria: The currently utilized anti-C5 antibody in paroxysmal nocturnal hemoglobinuria, eculizumab, targets MG7 domain in α-chain, preventing the interactions between C5 and C5 convertases [16, 44, 45].